TMS Therapy in Primary Care: Indications, Coding Guide

NP Chronicles · Clinical Deep-Dive

TMS in the Office: Indications, Devices, Coding, and Whether It Belongs in Primary Care

Transcranial Magnetic Stimulation is no longer just a psychiatry-only referral. Here's what NPs need to know before considering it as an in-office modality.

NEUROMODULATION • PRACTICE MANAGEMENT • BILLING & CODING • BOARD PREP INSIDE

Transcranial Magnetic Stimulation (TMS) has quietly moved from an academic curiosity to a billable, FDA-cleared, office-based treatment with a growing evidence base well beyond depression. For NPs in primary care, family medicine, or integrated behavioral health settings, the question isn't just "does TMS work?" — it's "does it make sense to bring in-house?"

What TMS Actually Does

TMS uses pulsed magnetic fields, delivered through a coil placed against the scalp, to induce small electrical currents in targeted cortical regions. Unlike electroconvulsive therapy, it requires no sedation, no seizure induction, and no recovery time — patients typically drive themselves to and from sessions and return to normal activity immediately afterward.

Clinical Bottom Line TMS is FDA-cleared for major depressive disorder (including anxious depression) and OCD, with additional clearances for smoking cessation and, more recently, adjunct use in adolescents aged 15–21 with MDD. Most other applications discussed below — chronic pain, PTSD, stroke rehab, Parkinson's, Alzheimer's, MS, schizophrenia — remain investigational and are not currently reimbursable for those indications.

Indications: Cleared vs. Investigational

Condition	FDA Status	Notes
Major Depressive Disorder	Cleared (2008)	First-line TMS indication; requires prior antidepressant failure
MDD with anxiety symptoms	Cleared	BrainsWay Deep TMS specifically cleared for "anxious depression"
Obsessive-Compulsive Disorder	Cleared (2018)	Reserved for patients who failed medication + psychotherapy
Smoking cessation	Cleared	Targets prefrontal cortex to reduce cravings
Adolescent MDD (ages 15–21)	Cleared (2025)	Adjunct therapy; multiple manufacturers now hold this clearance
Chronic pain / fibromyalgia	Investigational	May work partly via treatment of comorbid depression
PTSD	Investigational	Some benefit shown combined with cognitive processing therapy
Anxiety disorders (standalone)	Investigational	Not yet FDA-approved as a standalone indication
Stroke rehabilitation	Investigational	Adjunct to neurorehabilitation
Parkinson's disease	Investigational	Mixed evidence; DBS remains the FDA-approved neuromodulation option
Alzheimer's disease	Investigational	Long-term efficacy and mechanism still unclear
Multiple sclerosis	Investigational	No curative treatment established via TMS
Schizophrenia	Investigational	Evidence insufficient to support routine use

Nuance Worth Noting "FDA-cleared" and "insurance-reimbursable" are not the same thing, and neither guarantees "appropriate for your practice." A device can be cleared for an indication while payers still require documented failure of two adequate antidepressant trials, a specific diagnosis code, and treatment by (or under supervision of) a qualified, trained provider before they'll pay a claim.

Devices on the Market

Several manufacturers hold FDA clearance for TMS systems, and they differ meaningfully in coil design, treatment protocol length, and indication breadth:

• NeuroStar — the original FDA-cleared system (2008) for MDD; introduced the "Dash" protocol in 2016, shortening standard sessions from roughly 37 minutes to under 19 minutes, which meaningfully improves office throughput.
• BrainsWay Deep TMS — uses a helmet-style H-coil designed to reach broader and deeper cortical regions; holds three FDA-cleared indications (MDD with and without anxiety, OCD, smoking addiction) and an adolescent MDD adjunct clearance.
• MagVenture — cleared for MDD since 2015, with an expanded adolescent (ages 15–21) MDD indication cleared in 2025; markets itself on lower per-use operating costs since it doesn't require disposable components.
• Magstim — another established 510(k)-cleared system for MDD, widely used in both clinical and research settings.

A standard treatment course across these systems runs roughly 20–36 sessions delivered over 4–6 weeks, with daily weekday sessions being typical.

Case From Practice A patient with treatment-resistant depression — two failed adequate trials of different antidepressant classes — asks her primary care NP about TMS after seeing an ad. She has no psychiatric follow-up currently in place. Before referring, the NP confirms: does the receiving practice document motor threshold determination and cortical mapping at intake (billed once under 90867), and do they have a system for tracking session counts against the typical 20–36 session course? These aren't just billing details — incomplete documentation of the initial mapping session is one of the most common reasons TMS claims get denied.

Insurance and Coding: The Practical Reality

TMS billing runs through three CPT codes, and getting them right matters for both compliance and revenue:

CPT Code	Description	Frequency
90867	Initial treatment: cortical mapping, motor threshold determination, delivery, and management	Once per treatment course (not more than once per 6-week period)
90868	Subsequent delivery and management, per session	Once per session for the remainder of the course
90869	Subsequent delivery with motor threshold re-determination	Used only when treatment parameters require significant readjustment; not billed alongside 90867 or 90868

A few coding rules worth internalizing: 90867 should be reported only once per episode of care, not in conjunction with 90868 or 90869 on the same date. If a patient's course runs 30 sessions, the expected billing pattern is one 90867 plus 29 units of 90868 — mismatched counts are a common trigger for payer audits.

On the payer side, coverage has been expanding but remains diagnosis-specific. Most payers, including Medicare Administrative Contractors, require ICD-10 codes reflecting moderate-to-severe major depressive disorder (recurrent or single episode) or documented treatment-resistant depression, generally defined as failure of at least two adequate trials of different antidepressant medications. Some state Medicaid programs have only recently added TMS as a covered benefit, and prior authorization requirements vary widely by payer and even by specific CPT code within the same payer's policy.

Nuance Worth Noting Provider qualification requirements are payer-specific and often stricter than general "any licensed provider" assumptions. Many payers require the treating provider to have completed manufacturer training and to supervise sessions at a defined level (general vs. direct), and some explicitly require a psychiatrist or psychiatric provider for certain indications like treatment-resistant OCD. Before assuming an NP-led primary care practice can bill independently for TMS, verify your specific payer mix's provider and supervision requirements.

Does TMS Belong in Primary Care?

For most primary care and family practice settings, TMS is better framed as a referral decision than an in-house service line — at least initially. The capital cost of a device, the staff training and certification requirements, the session volume needed to make the investment worthwhile, and the payer documentation burden all favor practices with a behavioral health or psychiatric focus, or larger multi-specialty groups that can dedicate staff and space.

That said, there's a real role for primary care NPs even without owning a device:

• Recognizing candidates early. Patients with a documented history of two failed antidepressant trials are potential TMS candidates well before they reach a psychiatrist. Flagging this in your documentation smooths prior authorization for the referral.
• Managing the medical comorbidities that intersect with TMS candidacy. Depression and chronic pain frequently co-occur, and treating one can meaningfully affect the other — a useful framing when coordinating care with a TMS-providing practice.
• Screening for contraindications. Non-removable ferromagnetic metal in or near the head, implanted stimulators or pumps, and certain seizure histories are relevant to flag before referral.
• Setting expectations. Patients often arrive having seen consumer advertising that blurs cleared indications with investigational ones. Being able to explain, in plain terms, what's actually FDA-cleared versus still being studied builds trust and reduces disappointment.

For larger primary care-adjacent groups with integrated behavioral health, an in-house device becomes more plausible — particularly with shorter-protocol systems like NeuroStar's Dash, which improve daily patient throughput and make the economics of ownership more realistic.

Board Prep Corner

FDA-cleared TMS indications (know these cold): Major depressive disorder (2008), OCD (2018), smoking addiction, and adjunct therapy for adolescent MDD ages 15–21 (multiple manufacturers, 2025). Everything else — chronic pain, PTSD, anxiety disorders, stroke, Parkinson's, Alzheimer's, MS, schizophrenia — is investigational.

CPT code family: 90867 = initial (cortical mapping + motor threshold + delivery), billed once per course. 90868 = subsequent session, no threshold redetermination. 90869 = subsequent session WITH threshold redetermination; never billed same-day as 90867 or 90868.

Treatment-resistant depression, standard definition: Failure to achieve satisfactory improvement after two adequate trials of different antidepressant medications in the current episode — the threshold most payers use for medical necessity.

Typical course: 20–36 sessions delivered over 4–6 weeks, generally on a daily weekday schedule.

Test-writer trap: A question may present TMS as "safe for anyone since it's non-invasive." Ferromagnetic implants near the head and certain seizure histories are relevant contraindications/precautions to screen for before referral.

Practice Takeaways

• Don't conflate FDA clearance with insurance coverage — verify payer-specific diagnosis codes, documentation requirements, and provider qualifications before referring or considering an in-house program.
• Document antidepressant trial failures clearly and specifically (drug, dose, duration, outcome) — this is the single most useful thing primary care can do to smooth a future TMS referral.
• Frame investigational uses (chronic pain, PTSD, anxiety, neurodegenerative disease) accurately to patients who've seen marketing that overstates the evidence.
• For most primary care practices, TMS is a referral relationship to build, not a device to purchase — unless you're part of a larger group with integrated behavioral health infrastructure.

Quick Board-Prep Quiz

1. Which of the following is an FDA-cleared indication for TMS?

OCD received FDA clearance for TMS in 2018, reserved for patients who have not responded to medication and psychotherapy. Standalone anxiety disorders, Parkinson's disease, and MS remain investigational uses.

2. A patient is on session 15 of a 30-session TMS course with no change in treatment parameters. Which CPT code applies to this session?

90868 covers subsequent delivery and management without motor threshold redetermination — the code used for the majority of sessions after the initial 90867 setup. 90869 is reserved for sessions requiring threshold redetermination, and 90867 is billed only once per treatment course.

3. What is the standard definition of treatment-resistant depression used by most payers for TMS medical necessity?

Most payer policies define treatment resistance as failure to achieve satisfactory improvement after two adequate trials of different antidepressant medications in the current episode.

FAQ

Can a nurse practitioner independently bill for and supervise TMS treatment? +

It depends entirely on the payer. Provider qualification and supervision requirements vary by insurer and sometimes by specific indication — some payers require psychiatric provider involvement, particularly for OCD. Verify requirements with your specific payer mix before assuming NP-led billing is possible in your setting.

Is TMS covered by insurance for chronic pain or fibromyalgia? +

Generally no. Chronic pain and fibromyalgia remain investigational indications for TMS, not FDA-cleared uses, and are not typically reimbursable under standard TMS CPT codes. Any observed benefit in these conditions may be related to treatment of comorbid depression rather than a pain-specific mechanism.

How long does a typical TMS treatment course take?

A standard course runs 20 to 36 sessions delivered over 4 to 6 weeks, typically on a daily weekday schedule. Some newer protocols, such as NeuroStar's Dash, shorten individual session length to under 19 minutes without changing the overall course duration.

What should primary care screen for before referring a patient for TMS? +

Key screening points include non-removable ferromagnetic metal in or near the head, implanted stimulators or medical pumps, and relevant seizure history. Clear documentation of prior antidepressant trials (medication, dose, duration, and outcome) also meaningfully speeds prior authorization for the referral.

• U.S. Food & Drug Administration. 510(k) clearance summaries for transcranial magnetic stimulation devices (NeuroStar, BrainsWay Deep TMS, MagVenture MagVita, Magstim).
• Centers for Medicare & Medicaid Services. Local Coverage Article: Billing and Coding: Transcranial Magnetic Stimulation (TMS) in the Treatment of Adults with Major Depressive Disorder (A57072).
• American Medical Association. CPT codes 90867, 90868, 90869 — Other Psychiatric Services or Procedures.
• Manufacturer clinical and regulatory communications, BrainsWay Ltd. and MagVenture, regarding FDA clearance updates (2025–2026).

NP Chronicles © Clinical education for NP students and new graduates. This content is for educational purposes and does not replace individualized clinical judgment or payer-specific verification.